IO Biotech CEO Mai-Britt Zocca acquires $10,120 in firm inventory

Mai-Britt Zocca, the Chief Govt Officer of IO Biotech, Inc. (NASDAQ:IOBT), lately bought 12,500 shares of the corporate’s frequent inventory. The transaction, dated December 23, 2024, was executed at a median value of roughly $0.8096 per share, amounting to a complete funding of $10,120. The acquisition comes because the inventory exhibits sturdy momentum, with a 13% achieve over the previous week. In line with InvestingPro, analysts keep a bullish outlook with value targets starting from $6 to $12.

Following this acquisition, Zocca straight owns 49,891 shares of IO Biotech. Moreover, she maintains oblique possession of 26,580 shares by way of Zocca Consulting ApS, an organization she solely owns. Zocca is the CEO and a director at IO Biotech, a pharmaceutical agency headquartered in Copenhagen, Denmark. The corporate, at present valued at $50.79 million, maintains a robust stability sheet with additional cash than debt. Need deeper insights into insider buying and selling patterns and firm financials? InvestingPro provides 8 further key insights about IOBT’s monetary well being.

In different latest information, IO Biotech has secured a mortgage facility of as much as €57.5 million from the European Funding Financial institution (EIB) to advance its therapeutic most cancers vaccines, together with IO102-IO103. This funding is predicted to increase the corporate’s monetary runway into the second quarter of 2026. IO Biotech has additionally reported promising outcomes from a Section 2 trial of IO102-IO103, indicating potential in treating sufferers with metastatic non-small cell lung most cancers. Moreover, the corporate has revealed encouraging pre-clinical information for its second vaccine candidate, IO112.

IO Biotech has additionally enacted modifications to its company governance paperwork and financial calendar. Analyst companies Piper Sandler and Morgan Stanley (NYSE:MS) have maintained an Obese ranking on IO Biotech, whereas Jefferies and H.C. Wainwright saved their Purchase rankings. These rankings have been influenced by latest information from the European Society for Medical (TASE:PMCN) Oncology convention and summary information for IO Biotech’s IO102-103. Regardless of the corporate’s Section 3 trial not assembly the interim evaluation goal response fee, the Impartial (LON:IOG) Information Monitoring Committee really useful the continuation of the examine. These are latest developments for IO Biotech.

This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.